Research programme: eye disorders therapy - Alcon/Origenis

Drug Profile

Research programme: eye disorders therapy - Alcon/Origenis

Alternative Names: MOREsystem®

Latest Information Update: 12 Apr 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Developer Alcon; Origenis
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Eye-Disorders

Most Recent Events

  • 17 Oct 2008 Preclinical development is ongoing USA and Germany
  • 15 Oct 2008 Alcon Research and Origenis extend their research alliance for the treatment of eye disorders
  • 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top